TRACT Therapeutics

TRACT Therapeutics

TRACT Therapeutics is a biotechnology company developing immunotherapies using T regulatory cells to improve organ transplant outcomes.

TRACT Therapeutics is a biotechnology company developing immunotherapies using T regulatory cells to improve organ transplant outcomes that is headquartered in Chicago, Illinois and was founded in 2014 by Joseph Leventhal.

Cellular therapy is the core of TRACT Therapeutics focus as their proprietary technology has been developed in order to help restore the immune balance of patients that have received a solid organ transplant, as well as those with autoimmune diseases. The approach that was developed by TRACT to provide the therapeutics is based on a platform that also treats solid organ transplant patients and those with Crohn's Disease.

The treatment processes that TRACT uses to operate are started as soon as a patient that needs an organ transplant(s) can undergo a pre-transplant blood donation. TRACT provides the patient with cryopreserved white blood cells that are maintained through a proprietary process. The white blood cells are administered in order to down regulate transplant rejection as well as reduce and prevent inflammation.

TRACT's process was developed over the span of twenty years, and now involves the isolation and expansion of a patient's own naturally occurring T regulatory cells (Tregs).

Timeline

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

TRACT Therapeutics, Inc. Received FDA Approval for a Phase 2 Trial Using a Patient's Immune Cells to Prevent Organ Rejection

Business Wire

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.